Home › Companies › CABA

Cabaletta Bio, Inc.

CABA Rare disease Lead: Phase 1 7 Biotech Distilled articles ↓

Most recent annual filing: 2026-01-15

Pipeline (8 active programs)

resecabtagene autoleucel

rese-cel · CABA-201

Cell Target: CD19

Systemic Lupus Erythematosus Phase 1 intravenous Cellares
Lupus Nephritis Phase 1 intravenous Cellares
Dermatomyositis Phase 1 intravenous Cellares
Immune-Mediated Necrotizing Myopathy Phase 1 intravenous Cellares
Systemic Sclerosis Phase 1 intravenous Cellares
Generalized Myasthenia Gravis Phase 1 intravenous Cellares
Pemphigus Vulgaris Phase 1 intravenous Cellares
Autoimmune Diseases Phase 1 intravenous Cellares

Technology platforms

CABA

Cabaletta Approach to B cell Ablation (CABA) platform using the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) approach, designed to reset the immune system via deep B cell depletion. Focus area: broad range of autoimmune diseases with B cell involvement.

Targets: CD19

Cell Shuttle · Cellares

Cellares Cell Shuttle — automated, closed, end-to-end CAR T cell manufacturing platform designed to improve reproducibility, scalability, and process control for autologous cell therapy production; applied to rese-cel manufacturing in the RESET clinical program

Biotech Distilled coverage (7)

2026-05-15 UPDATE: Cabaletta Bio (CABA) - The No-Chemo Gambit Actually Worked at the Lowest Dose 🔒 Paid
2026-05-04 UPDATE: Cabaletta Bio (CABA) - The Dilution Gap Just Closed. And Eli Lilly Brought a Chair.
2026-04-29 UPDATE: Cabaletta Bio (CABA) - The Factory Just Got Locked In for a Decade 🔒 Paid
2026-03-29 UPDATE: Cabaletta Bio (CABA) - The FDA Hits the Brakes on the Fast Track 🔒 Paid
2026-02-21 UPDATE: Cabaletta (CABA) - The Smart Money is Anchoring 🔒 Paid
2026-01-13 Update: Cabaletta Bio (CABA) – The 2026 Strategy Reset 🔒 Paid
2026-01-08 Cabaletta Bio (CABA): Scientific Due Diligence for Rese-Cel and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.